3m Innovative Properties Company

Coley Pharmaceutical Group, Inc.

Scott E Langer

Tushar A Kshirsagar

Philip D Heppner

George W Griesgraber

Kyle J Lindstrom

Shri Niwas

David T Amos

Karl J Manske

Jerald K Rasmussen

Bryon A Merrill

Mahfuza B Ali

Joseph F Dellaria, Jr

Gregory J Marszalek

Bernhard M Zimmermann

Gregory D Lundquist, Jr

Sarah J Slania

Bathsheba E Chong Conklin

Andrew P Klein

Larry R Krepski

Michael E Danielson

Joshua R Wurst

Joan T Moseman

Sarah C Slania

Described herein are absorbent articles and methods of making such articles. The articles are made by bonding a copolymer onto a substrate to form a core. The absorbent articles are particularly useful in personal care product, e.g., disposable hygiene products.

Absorbent articles and methods of making

Described herein are absorbent articles made by bonding a copolymer onto a substrate to form a core. The absorbent articles are particularly useful in personal care product, e.g., disposable hygiene products. In some embodiments, the absorbent article includes a first substrate; and a copolymer irreversibly bonded onto the first substrate to form a core, wherein the copolymer is derived from a polymerizable solution comprising: (a) a first monomer selected from a (meth)acrylic acid or salt thereof; (b) greater than 1 wt % of a second monomer, wherein the second monomer is a hydrophilic crosslinking monomer, and (c) a polymeric porogen.

A method of preferentially inducing IFN-&#x3b1; biosynthesis in an animal comprising administering certain imidazo[4,5-c] ring compounds with a hydroxymethyl or hydroxyethyl substituent at the 2-position or pharmaceutical compositions containing the compounds, intermediates, methods of making, and methods of using these compounds a immunomodulators for treatment of diseases including viral and neoplastic diseases comprising preferentially inducing IFN-&#x3b1; biosynthesis in an animal are disclosed.

Method of preferentially inducing the biosynthesis of interferon

Imidazo-containing compounds (e.g., imidazoquinolines, imidazonaphthyridines, and imidazopyridines) with an oxime substituent at the 1-position, pharmaceutical compositions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.

Oxime substituted imidazo-containing compounds

1H-Imidazo[4,5-c]quinolin-4-amines with a hydroxy, alkoxy, hydroxyalkoxy, or alkoxyalkoxy substituent at the 2-position, pharmaceutical compositions containing these compounds, methods of making the compounds, intermediates, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.

Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods

Certain imidazonaphthyridines with a hydroxymethyl or hydroxyethyl substituent at the 2-position, pharmaceutical compositions containing the compounds, intermediates, methods of making and methods of use of these compounds as immunomodulators, for preferentially inducing IFN-&#x3b1; biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.

Hydroxyalkyl substituted imidazonaphthyridines

1H-Imidazo[4,5-c]naphthyridin-4-amines with a hydroxy, alkoxy, hydroxyalkoxy, or alkoxyalkoxy substituent at the 2-position, pharmaceutical compositions containing these compounds, methods of making the compounds, intermediates, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.

[object Object]

Certain imidazoquinolines with a hydroxymethyl or hydroxyethyl substituent at the 2-position, pharmaceutical compositions containing the compounds, intermediates, methods of making and methods of use of these compounds as immunomodulators, for preferentially inducing IFN-&#x3b1; biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.

Hydroxyalkyl substituted imidazoquinolines

1H-Imidazo ring systems (e.g., imidazopyridines, imidazoquinolines, imidazonaphthyridines, 6,7,8,9-tetrahydro imidazoquinolines and imidazonaphthyridines) with an amino substituent at the 2-position, pharmaceutical compositions containing these compounds, methods of making the compounds, intermediates, and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.

[1,2]Imidazo[4,5-c] ring compounds (e.g., imidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and imidazo[4,5-c]pyridines) substituted with a fused ring containing an oxygen and/or nitrogen atom attached at the 1- and/or 2-position, pharmaceutical compositions containing the compounds, intermediates, methods of making the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.

Imidazo-containing compounds (e.g., imidazoquinolines, imidazonaphthyridines, imidazopyridines) with a hydrox-ylamine substituent at the 1-position, pharmaceutical compositions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.

Growing community of inventors

Woodbury, MN, United States of America

Scott E Langer